Integrated targeted whole-genome and RNA-sequencing analysis of an intronic GNE variant in GNE myopathy Authors: Nozomi Toide, Ryo Iwase, Mitsugu Yanagidaira, Sumihito Togi, Hiroki Ura, Makiko Egawa, Eriko Takamine, Hiroya Kuwahara, Sonoko Misawa, Masayuki Yoshida, Yo Niida, Taro Ishiguro Published: 2026 ABSTRACT GNE myopathy is a rare autosomal recessive myopathy caused by biallelic pathogenic variants in GNE, which encodes an essential enzyme for sialic acid biosynthesis. Most variants are located in exonic regions, whereas significance of intronic variants remains unclear, leaving many suspected cases genetically unresolved. We aimed to assess the pathogenicity of intronic GNE variants using targeted whole-genome and RNA sequencing. We performed combined long amplicon sequencing in two siblings with GNE myopathy. DNA and RNA were extracted from muscle biopsy specimens and peripheral blood mononuclear cells. Variants were validated using Sanger sequencing. Splicing effects were predicted using SpliceAI and SpliceRover and validated by RNA sequencing. Muscle sialylation was assessed using peanut agglutinin lectin staining. An uncharacterized intronic variant, NC_000009.12(NM_001128227): c.1163+5G>T, was identified in trans with a known missense variant (NM_001128227): c.1807C>G, p.V603L. RNA sequencing demonstrated aberrant splicing caused by intronic mutation, leading to a non-productive transcript in muscle and blood cells. Reduced sialic acid biosynthesis further supported the pathogenicity of the intronic mutation. These findings demonstrate that combined long amplicon sequencing can elucidate the genetic basis of GNE myopathy undetectable by exome sequencing. This approach provides a clinically applicable, less invasive diagnostic strategy and expands the spectrum of pathogenic GNE variants. Introduction GNE myopathy is a rare autosomal recessive neuromuscular disorder characterized by distal muscle weakness in adults. It was first described in 1981 by Nonaka et al. as “distal myopathy with rimmed vacuoles” in Japanese patients1. Although this disease progresses slowly, it may cause wheelchair dependence. Previous studies involving muscle MRI have indicated that fat replacement is selectively observed in the tibialis anterior muscle and hamstrings, whereas the quadriceps femoris is spared, which is a characteristic clinical manifestation of GNE myopathy2. Rimmed vacuoles are characteristically observed in muscle histopathology. GNE myopathy emerges from biallelic pathogenic variations in the GNE gene, which is located on chromosome 9 and includes 13 exons. GNE encodes the bifunctional enzyme uridine diphosphate (UDP)-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, a key regulator of sialic acid biosynthesis3,4. Sialic acids occupy the terminal ends of oligosaccharide chains of membrane glycoproteins in most cells and participate in cytoskeletal stability, cell recognition, and intercellular communication5. In skeletal muscle cells, sialic acids are present on membrane proteins, such as α-dystroglycan and neural cell adhesion molecule, suggesting their potential role in maintaining membrane integrity during muscle contraction and in the mechanisms of reinnervation. Reduced sialylation of α-dystroglycan and neural cell adhesion molecule has been reported in GNE myopathy, suggesting the involvement of these sialic acid-bearing proteins in the disease pathogenesis6,7. A definitive diagnosis of GNE myopathy requires genetic testing. More than 150 GNE variants associated with GNE myopathy have been reported, most of which are missense or nonsense variants of exonic lesions. Intronic mutations have been identified in patients clinically diagnosed with GNE myopathy; however, these non-coding variants are rarely considered in clinical settings owing to the insufficient knowledge regarding their functional consequences and a limited understanding of genotype–phenotype correlations8. Whole-exome sequencing (WES) and targeted gene panel sequencing have become first-line diagnostic tools for hereditary disorders, and recent technical improvements have enabled partial coverage of exon–intron boundary regions. However, it has been reported that splice-adjacent intronic mutations may still be missed in routine clinical WES analyses owing to insufficient capture efficiency, unstable read mapping, and exclusion by quality control filtering pipelines9. Moreover, the pathogenicity of detected splicing variants often remains uncertain when assessed solely by in silico prediction tools. Consequently, the contribution of intronic variants to GNE myopathy may be underestimated in current diagnostic workflows. Combined long amplicon sequencing (CoLAS), developed by Niida and co-workers10, integrates target-specific long-range PCR with full-length cDNA-sequencing within a single analytical framework, enabling direct detection and functional validation of aberrant splicing events. We propose that RNA-based approaches such as CoLAS serve as a complementary diagnostic strategy in cases in which intron-adjacent variants are suspected but consistently missed by capture-based next-generation sequencing, or when the pathogenicity of candidate variants cannot be conclusively established at the DNA level. Hence, we aimed to investigate the role of intronic variants of GNE in patients with GNE myopathy by combining targeted WGS and RNA sequencing. In this study, we identified a novel intronic GNE variant that induces aberrant RNA splicing, leading to non-productive transcription and decreased sialic acid production. Our study highlights that comprehensive genetic analysis using targeted WGS and RNA sequencing aids in elucidating the genetic basis of previously unresolved GNE myopathy cases. Materials and methods Ethical compliance and specimens All clinical information and specimens used in this study were obtained for diagnostic purposes. Written informed consent for genetic analysis was obtained from the patient, her sibling, and her parents. This study was approved by the Ethics Committee of the Institute of Science, Tokyo Hospital (No. G2000-198). The peroneus longus muscle from the patient and blood samples from her sibling and parents were obtained at the Institute of Science, Tokyo Hospital. Gene analysis with CoLAS In this study, CoLAS was performed at the Center for Clinical Genomics, Kanazawa Medical University Hospital, Uchinada, Japan. The CoLAS method involves the combination of very long-range PCR amplicon sequencing and long-range reverse transcription–PCR amplicon sequencing10,11. DNA and RNA were extracted from the patient’s muscle tissue, as well as from the peripheral blood of the patient, her parents, and her sibling, using standard methods, as described previously12,13. Combined long-amplicon sequencing targeting GNE and data analysis was performed using the established protocols10,11. Briefly, overlapping long-range PCR primer sets were designed to cover the entire GNE genomic region (20–22 kb per amplicon) and were multiplexed into four groups. Sequencing libraries were prepared from the PCR amplicons and analyzed via next-generation sequencing according to the standard procedures of the facility. An Integrative Genomic Viewer (IGV version 2.4.13) was used for visualization14. SpliceAI and SpliceRover were used to predict the strength of the donor and acceptor sites affected by the variant15,16. The identified variants were confirmed in the patient, her sibling, and her parents via Sanger sequencing. The variants were named according to the reference sequence of the Locus Reference Genomic sequence. The Genome Aggregation Database (gnomAD), dbSNP (National Center for Biotechnology Information (NCBI)), Japanese Multi Omics Reference Panel (jMorp), and ClinVar databases were used for variant annotation17–20. Peanut agglutinin (PNA) lectin staining Briefly, a biopsy was obtained from the patient’s peroneus longus muscle. The frozen tissue was sectioned into 10-μm slices using a cryostat and fixed in cold acetone (NACALAI TESQUE, 00310-95) for 10 min. After washing with PBS (positive control), the samples were incubated with 200 U of neuraminidase (NACALAI TESQUE, 24229-74) for 1 h at 37 °C and washed with PBS. The samples were pre-incubated with PBS containing 1% bovine serum albumin at room temperature (22–25 °C) for 1 h and washed with PBS. Subsequently, they were incubated with 5 μg/ml FITC-labeled PNA (Vector Labs, FL-1071) in the dark at room temperature for 1 h. After washing with PBS, the samples were mounted in 4′,6-diamidino-2-phenylindole-containing medium (Vector Labs, H-1200) and examined under a fluorescence microscope (KEYENCE BZ-X700; KEYENCE, Osaka, Japan) at emission and absorption wavelengths of 470 nm and 525 nm, respectively. Results Clinical details The index case was a Japanese woman (patient 1) who developed distal dominant bilateral lower limb weakness, followed by upper limb involvement (Fig. 1A). The symptoms were initially noted after her first childbirth at the age of 20 years and worsened after her second childbirth. She was referred to our hospital at the age of 29 years. She exhibited weakened tibialis anterior, whereas the quadriceps were unaffected. MRI revealed marked atrophy and fatty infiltration of the posterior thigh (hamstring) and bilateral flexor and extensor muscles of the calf, consistent with GNE myopathy (Fig. 1B). The muscle biopsy of her peroneus longus revealed rimmed vacuoles on hematoxylin–eosin and metachromatic granule staining, without evident inflammatory findings (Fig. 1C). These clinical and pathological findings suggest GNE myopathy.Fig. 1Pedigree, muscle imaging, and histopathology.A The pedigree of the patient. P proband. P1, patient 1; P2, patient 2. B MRI of patients 1 and 2. Short T1 inversion recovery (STIR) imaging shows atrophy and fatty infiltration of the hamstrings and lower extremity muscles, whereas the quadriceps are preserved in patient 1. In patient 2, STIR imaging shows marked atrophy of the tibialis anterior muscle. C Histopathological image of the peroneus longus muscle of patient 1. Hematoxylin and eosin staining reveals marked variations in fiber diameter, rounded fibers, slight fatty infiltration, and rimmed vacuoles. Gomori trichrome staining reveals granular red material within and around the vacuoles. CD3 and CD8 staining shows that inflammatory cell infiltration is not prominent. Pedigree, muscle imaging, and histopathology. A The pedigree of the patient. P proband. P1, patient 1; P2, patient 2. B MRI of patients 1 and 2. Short T1 inversion recovery (STIR) imaging shows atrophy and fatty infiltration of the hamstrings and lower extremity muscles, whereas the quadriceps are preserved in patient 1. In patient 2, STIR imaging shows marked atrophy of the tibialis anterior muscle. C Histopathological image of the peroneus longus muscle of patient 1. Hematoxylin and eosin staining reveals marked variations in fiber diameter, rounded fibers, slight fatty infiltration, and rimmed vacuoles. Gomori trichrome staining reveals granular red material within and around the vacuoles. CD3 and CD8 staining shows that inflammatory cell infiltration is not prominent. Furthermore, her older brother (patient 2) developed distal muscle weakness (Fig. 1A). His initial symptoms were noted at the age of 33 years, and he was referred to our hospital at 35 years of age. He also exhibited weakness of the tibialis anterior muscle. MRI revealed marked atrophy and fatty infiltration in both tibialis anterior muscles (Fig. 1B). Consistent with the findings of his sister, GNE myopathy was suspected. Gene analysis Combined long-amplicon sequencing was performed on the genomic DNA from the peripheral muscle tissue of patient 1. DNA-sequencing revealed a known pathogenic single-nucleotide variant (SNV) in exon 10 (NC_000009.12 (NM_001128227): c.1807C>G, p.V603L) and an additional variant in intron 6 (NC_000009.12 (NM_001128227): c.1163+5G>T) (Supplementary Fig. 1), and no additional candidate variants were identified. The c.1163+5G>T variant is listed in gnomAD v4.1.0 at a very low frequency (allele frequency = 6.516 × 10−7, allele count = 1/1,534,628) in the total population. The variant is not listed in dbSNP (NCBI) or jMorp. In addition, ClinVar indicates no prior reports of this variant in GNE myopathy. Sanger sequencing of the genomic DNA was performed to confirm the detected variants (Fig. 2A). In the peripheral blood mononuclear cells of patient 2, the c.1163+5G>T variant was identified together with a known Exon 10 SNV (c.1807C>G, p.V603L). Analysis of parental blood samples demonstrated that the c.1163+5G>T variant was present in the father and the c.1807C>G, p.V603L variant was present in the mother, confirming that the c.1163+5G>T variant was in trans in the siblings.Fig. 2Gene analysis.A Sanger sequencing of the genomic DNA of patients 1 and 2. In the genomic DNA, c.1807C>G (p.V603L) and c.1163+5G>T are identified in both siblings (patient 1 is shown). B Schematic image of the splicing aberration caused by c.1163+5G>T. RNA analysis suggests that the intron 6 variant causes exon 6 skipping and a 16-bp deletion at the 3ʹ end of exon 6 owing to the activation of a cryptic donor site. C Integrative Genomic Viewer image of the Sashimi plot in patients 1 and 2. The junctional read counts show the expression ratios of normal splicing (p.V603L allele), normal splicing (c.1163+5G>T allele), cryptic donor site usage, and exon 6 skipping. C, cytosine; Ct, control; G, guanine; Leu, leucine; NMD, nonsense-mediated mRNA decay; Pt, patient; T, thymine; Val, valine; WT, wild type. Gene analysis. A Sanger sequencing of the genomic DNA of patients 1 and 2. In the genomic DNA, c.1807C>G (p.V603L) and c.1163+5G>T are identified in both siblings (patient 1 is shown). B Schematic image of the splicing aberration caused by c.1163+5G>T. RNA analysis suggests that the intron 6 variant causes exon 6 skipping and a 16-bp deletion at the 3ʹ end of exon 6 owing to the activation of a cryptic donor site. C Integrative Genomic Viewer image of the Sashimi plot in patients 1 and 2. The junctional read counts show the expression ratios of normal splicing (p.V603L allele), normal splicing (c.1163+5G>T allele), cryptic donor site usage, and exon 6 skipping. C, cytosine; Ct, control; G, guanine; Leu, leucine; NMD, nonsense-mediated mRNA decay; Pt, patient; T, thymine; Val, valine; WT, wild type. As the c.1163+5G>T intronic variant was located at the splice donor site, it was assumed that the variant affected the splicing outcome. As expected, SpliceAI predicted donor loss in exon 6 (donor loss score, 0.97; acceptor loss score, 0.87) (Supplementary Fig. 2). Additionally, SpliceRover predicted loss of the donor site in exon 6, as well as generation of a novel donor splice site upstream of the canonical donor site (c.1163-16*) (Supplementary Fig. 3). Consistent with the prediction, the exon 5–7 junction lead and the exon 6–7 lead with a 16-bp deletion at the 3ʹ side of exon 6, both resulting in frameshift, were detected via RNA sequencing (Fig. 2B). At the c.1807C>G position in exon 10, the allele harboring the c.1163+5G>T intron variant had an expression ratio of ~52%, as determined by allele-specific read counts (C:1302; G:1213). Therefore, in the IGV Sashimi plots of patient 1’s muscle tissue, junctional read counts showed that exon 6 skipping accounted for ~20% (560 reads), whereas the 16-bp deletion of exon 6 at the 3ʹ side constituted ~7.5% (204 reads). Normal exon 6–7 splicing was observed in ~24% (648 reads) of the alleles harboring the novel intron 6 variant and in ~48% (1,304 reads) of the alleles carrying the exon 10 missense variant (Fig. 2C). In the peripheral blood mononuclear cells of patient 2, the IGV Sashimi plot analysis of junctional read counts showed that exon 6 skipping accounted for ~10% (146 reads), and the 16-bp deletion constituted ~10% (123 reads). Normal exon 6–7 splicing was observed in ~20% (288 reads) of the alleles harboring the novel intron 6 variant and in ~60% of the alleles carrying the exon 10 variant (Fig. 2C). PNA lectin staining Finally, to assess the phenotypic consequences of the novel mutation, sialic acid biosynthesis was assessed in the patient’s muscle tissues using PNA lectin staining. PNA specifically binds to desialylated core 1 mucin-type O-glycans (Galβ1-3GalNAcα1-Ser/Thr) on the cell surface. In the control muscle tissue, PNA fluorescence was barely detectable under normal conditions but became evident after neuraminidase treatment, which removes sialic acid from glycoproteins (Fig. 3A, B). By contrast, PNA staining of the peroneus longus muscle of patient 1 exhibited clear membrane fluorescence without neuraminidase treatment, indicating reduced sialylation and impaired sialic acid synthesis (Fig. 3C, D). These findings suggest reduced sialylation in the patient’s muscle.Fig. 3Peanut agglutinin lectin staining.A FITC-conjugated PNA staining of the control shows barely detectable fluorescence signal. B After the neuraminidase treatment of the control, the PNA signal increases notably. C FITC-conjugated PNA staining of patient 1’s specimen shows an increased signal along the sarcolemma. D After neuraminidase treatment of patient 1, the PNA signal remains unchanged. Scale bar, 50 μm. Ct, control; DAPI, 4′,6-diamidino-2-phenylindole; FITC-PNA, fluorescein isothiocyanate-labeled peanut agglutinin; Pt, patient. Peanut agglutinin lectin staining. A FITC-conjugated PNA staining of the control shows barely detectable fluorescence signal. B After the neuraminidase treatment of the control, the PNA signal increases notably. C FITC-conjugated PNA staining of patient 1’s specimen shows an increased signal along the sarcolemma. D After neuraminidase treatment of patient 1, the PNA signal remains unchanged. Scale bar, 50 μm. Ct, control; DAPI, 4′,6-diamidino-2-phenylindole; FITC-PNA, fluorescein isothiocyanate-labeled peanut agglutinin; Pt, patient. Discussion In this study, we identified the SNV c.1163+5G>T in the GNE gene, which caused abnormal splicing, resulting in exon 6 skipping and a 16-bp deletion at the 3’ end of exon 6. This produced a non-productive transcript associated with reduced sialic acid levels on the muscle cell membrane, representing a phenotypic manifestation in a single family with GNE myopathy. Although several intronic variants of GNE have been cataloged in population databases, such as ClinVar, only a limited number has been functionally validated in patients. Our findings provide additional direct evidence that an intronic variant causes aberrant splicing and contributes to the pathogenesis of GNE myopathy, consistent with recent reports by Jiao et al.21. Notably, by integrating targeted whole-genome sequencing and RNA sequencing using peripheral blood cells, our approach suggests the potential utility of a less invasive and less sampling bias strategy that may serve as an alternative or complement to muscle biopsy for detecting pathogenic splicing abnormalities. Theoretically, WGS reveals intron variants that are missed by WES. Recent advances in in silico splicing prediction tools have improved the prediction of the functional impact of these variants. However, such non-coding region mutations are rarely considered in clinical practice owing to the insufficient evidence to support their interpretation. Although the c.1163+5G>T variant has been registered as a single allele in gnomAD, its pathogenic significance has not been determined. In the present study, we used the CoLAS approach, which integrates targeted whole-genome and RNA sequencing, allowing the interpretation of the pathogenic significance of an intronic variant. Furthermore, in patient 2, the same variant was detected in peripheral blood mononuclear cells, resulting in identical aberrant splicing. Although RNA sequencing facilitates the interpretation of intronic variants, its clinical application has been limited to cases in which relevant organs are known and accessible for biopsy22. Several studies have demonstrated that many known neuromuscular disease-related genes are downregulated in clinically accessible tissues, such as the whole blood and skin, making their detection challenging22,23. In this study, identical aberrant splicing was detected in RNA analysis not only in muscle tissue but also in peripheral blood cells. Previous studies have reported hematological abnormalities, particularly thrombocytopenia, associated with GNE variants24,25. Thrombocytopenia has been reported in patients with GNE myopathy carrying compound heterozygous variants in the kinase domain, and lectin microarray analyses of platelets have demonstrated reduced α2,3-sialylation of platelet surface glycans26. These findings suggest that hyposialylated platelets may be cleared via hepatic Ashwell–Morell receptors or macrophage lectin receptors. Sialic acid supply to tissues is thought to occur through multiple pathways, including systemic distribution of plasma-sialylated glycoproteins synthesized in the liver or derived from dietary intake, de novo synthesis within individual tissues and salvage pathways recycling sialic acid from intracellular and cell surface glycoproteins and glycolipids27. Notably, hepatic GNE expression and enzymatic activity are higher than those in other organs, and the liver is considered the primary site of systemic sialic acid biosynthesis28. Consistent with this, reduced levels of free sialic acid in the serum of patients with GNE myopathy have been reported29. By contrast, it has been reported that major liver-derived glycoproteins such as transferrin and apolipoprotein C-III do not exhibit hyposialylation in patients with GNE myopathy30, indicating that the relationship between systemic sialic acid metabolism and tissue-specific sialylation abnormalities remains incompletely understood. Therefore, whether the splicing defect observed in blood cells in this study directly contributes to platelet hyposialylation requires further investigation. Nevertheless, the identification of GNE splicing abnormalities in clinically accessible blood cells suggests that RNA-based analyses can provide a feasible approach to interrogate the in vivo functional impact of intronic variants. Some cases exhibit the clinical manifestations of GNE myopathy, despite the identification of GNE mutations only in heterozygous alleles, suggesting that the prevalence of intronic variants that affect alternative splicing is underestimated. Therefore, WGS covering the intronic region is crucial for comprehensive variant detection. A possible explanation for this notion is that the GNE gene is rich in Alu sequences, a type of short interspersed nuclear element, making it susceptible to large genomic rearrangements31,32. Notably, using WGS, previous studies have revealed copy number variants in patients harboring only monoallelic GNE mutations. Genotype–phenotype correlations in GNE myopathy are garnering attention in cohort studies, which have revealed that specific GNE variants are associated with distinct patterns of disease progression and severity33,34. In Japanese patients, homozygosity for p.V603L results in a rapidly progressive disease course with a median “time to loss of ambulation” of ~10 years, whereas compound heterozygosity for p.D207V and p.V603L has been associated with a milder clinical course35. Furthermore, patients carrying mutations in both enzymatic domains of GNE tend to present earlier onset and loss of ambulation than those with two mutations within the same domain36. In this study, patients 1 and 2 harbored the same mutations; however, patient 1, in her 20s, developed symptoms more than 10 years earlier and exhibited faster disease progression than patient 2. A possible explanation is that exon 10, which harbors the p.V603L variant, encodes a kinase domain in which the mutation–clinical course relationship appears to be relatively consistent, whereas the aberrant splicing rate caused by the c.1163+5G>T variant varies among individuals. This variability may lead to differences in protein expression through nonsense-mediated mRNA decay. However, we observed tissue-specific splicing patterns in distinct tissues (skeletal muscle and blood) in this study; therefore, directly correlating these splicing differences with interindividual clinical phenotypes has limitations. Furthermore, although GNE is predominantly expressed in the liver, which has a central role in systemic sialic acid biosynthesis, we did not evaluate splicing efficiency in hepatic tissue. Consequently, we were unable to determine whether systemic changes correlate with localized clinical manifestations, such as the severity of muscle weakness. Nevertheless, our findings suggest that intronic variants can induce variable degrees of aberrant splicing across tissues, potentially contributing to the phenotypic heterogeneity observed in GNE myopathy. Another factor that potentially contributed to the earlier onset in patient 1 was pregnancy. Although no direct link has been established, the onset of GNE myopathy occurs during reproductive age, and pregnancy may aggravate the disease owing to increased sialic acid requirements and its impact on overall muscle strength36. For example, a few case reports have described the emergence or marked worsening of motor symptoms in patients with GNE myopathy during pregnancy37. By contrast, other studies have reported disease onset or exacerbation within 1 year after delivery in some patients38. In this case, reduced sialylation of the muscle cell membrane was associated with the c.1163+5G>T variant. However, the precise relationship between the impaired sialic acid biosynthesis caused by reduced UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and muscle atrophy or weakness remains unclear36. Sialic acid has a crucial role in suppressing the generation of reactive oxygen species during muscle contraction, and a decreased biosynthesis of sialic acid may result in increased reactive oxygen species production, the upregulation of atrogenes, and myofiber atrophy39. Conversely, cytoskeletal and sarcomeric alterations have been reported in muscles with GNE mutations, suggesting that, in addition to impaired sialic acid biosynthesis, GNE mutations contribute to reduced cell motility in myofiber formation through abnormal interactions with α-actinin-1 and α-actinin-2 (ref. 40). This study demonstrated that a novel SNV in GNE that leads to aberrant splicing is associated with reduced sialylation in skeletal muscle and disease manifestation. Although this study primarily focussed on genetic analysis without considering the precise impact of this mutation on sialic acid metabolism or disease onset mechanisms using cell or animal models, these findings may inform the development of novel therapies targeting splicing abnormalities. Supplementary information supplementary figure 1 supplementary figure 2 supplementary figure 3 supplementary figure 1 supplementary figure 2 supplementary figure 3